NCT00958776终止3 期
A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 405
- 试验地点
- 40
- 主要终点
- Time to Clinical Resolution (Kaplan-Meier Estimate)
研究概览
简要总结
A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥12 years of age, male or female.
- •Able to provide informed consent, or for whom consent may be provided by guardian, unless informed consent provided by a guardian or a legally authorized representative is not consistent with applicable local or ethical concerns, procedures, directives and/or guidelines.
- •Subject must have at least one of the following clinical presentations at Screening:
- •Oral temperature ≥ 38.0 °C (≥100.4 °F), ≥38.6°C (≥101.4 °F) tympanic or rectal OR
- •Oxygen saturation <92%, OR
- •Two out of the following three vital signs:
- •Respiration rate >24/minute, Heart rate >100/minute, Systolic BP <90 mmHg
- •Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion) of any severity (mild, moderate, or severe).
- •Presence of at least one constitutional symptom (headache, myalgia, feverishness, or fatigue) of any severity (mild, moderate, or severe).
- •Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as the earlier of either (1) the time when the temperature was first measured as elevated, OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
- •Severity of illness that, in the Investigator's judgment, justifies hospitalization of the subject for supportive care.
- •Presence of one or more of the following factors:
- •Age ≥60 years. Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy.
- •Current history of congestive heart failure or angina. Presence of diabetes mellitus, clinically stable or unstable. Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value (an investigative site at altitude >2000 ft above sea level will utilize different criteria for oxygen saturation).
- •History of chronic renal impairment not requiring peritoneal dialysis. Serum creatinine > 2.0 mg/dL or > 177 μmol/L.
- •Diagnosis of Influenza by satisfying one of the following:
- •Clinical Influenza with Positive Diagnostic Test. Subjects who have a positive rapid antigen test (RAT) for influenza A and/or influenza B (using a Sponsor-approved test kit), or positive test (using other methodology) for influenza A and/or B virus antigen or RNA performed in a clinical laboratory at the screening/enrollment evaluation are eligible for enrollment.
- •Clinical Influenza with Negative Rapid Antigen Test (RAT). Subjects with a negative RAT test may be enrolled once the site has been approved by the Sponsor to enroll such subjects, based on documentation of an outbreak of influenza in the community. An influenza outbreak may be documented in the catchment area of the hospital via one of the following methods: 1) local confirmation of influenza A or B infection in the current influenza season by a) the institution's local laboratory, or b) the local public health system, or c) the national public health system, or d) a laboratory of a recognized multinational influenza surveillance scheme such as the European Influenza Surveillance Network (EISN); 2) prior enrollment of a RAT positive subject into this study at the same institution in the current influenza season.
排除标准
- •Subjects who have been hospitalized for greater than 24 hours (not including time spent in the Emergency Department).
- •Treatment with any dose(s) of rimantadine, amantadine, ribavirin, zanamivir, or oseltamivir in the previous 7 days.
- •Blood platelet count of < 20 x 109/L at the time of the screening evaluation.
- •Serum bilirubin > 6 mg/dL or > 105 μmol/L at time of screening evaluation.
- •Serum ALT or AST > 5 times the upper limit of normal at time of screening evaluation.
- •Congestive heart failure of NYHA Class III or Class IV functional status.
- •Serum creatinine > 5.0 mg/dL or > 500 μmol/L at time of screening evaluation.
- •Subjects who require peritoneal dialysis.
- •Altered neurologic status as defined by a Glasgow Coma Score of ≤ 9, unless medically induced.
- •Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or breastfeeding.
- •Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy. Subjects who have completed treatment 30 days prior to enrollment are not excluded. Hormone treatment for cancer is also not excluded.
- •Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
- •HIV infection with a known CD4 count < 200 cells/mm3 unless on a stable highly active antiretroviral therapy (HAART) for at least 6 months.
- •Presence of a pre-existing chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). Subjects with chronic osteomyelitis or Hepatitis B or C not requiring treatment are not excluded.
- •Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
- •Previous treatment with intravenous or intramuscular peramivir.
- •Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the screening evaluation.
- •Subjects diagnosed with Cystic Fibrosis.
- •Subjects with confirmed clinical evidence of acute non-influenzal infection at the time of screening evaluation.
- •Subjects who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
研究组 & 干预措施
Peramivir+SOC
Experimental
- Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
- Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
干预措施: Peramivir+SOC (Drug)
Placebo+SOC
Placebo Comparator
Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
干预措施: Placebo+SOC (Drug)
结局指标
主要结局
Time to Clinical Resolution (Kaplan-Meier Estimate)
时间窗: 10 days
Time to clinical resolution was defined as the time in hours from initiation of study treatment until normalization of at least 4 of the 5 signs within the respective normalization criteria, maintained for at least 24-hours. Time to clinical resolution was summarized by treatment group using the method of Kaplan-Meier. For subjects who did not experience clinical resolution, values were censored at the date of their last non-missing assessment of clinical resolution during the study (whether this assessment occurred as an inpatient or as an outpatient).
次要结局
- Change (Reduction) in Influenza Virus Titer(Baseline and 24, 48, 108 hours)
- Time to Alleviation of Clinical Symptoms of Influenza(10 days)
- Time to Resolution of Fever (Kaplan-Meier Estimate)(10 days)
- Time to Resumption of Usual Activities(10 days)
- Number of Subjects With ICU Admission(10 days)
- Duration of All ICU Admissions (Kaplan-Meier Estimate)(10 days)
研究者
研究点 (40)
Loading locations...
相似试验
已完成
3 期
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerHER2-positive Breast CancerNCT03588091Jiangsu HengRui Medicine Co., Ltd.355
招募中
3 期
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06022861Shandong Boan Biotechnology Co., Ltd510
尚未招募
3 期
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic AcidImaging Examination Shows at Least One Site With Bone Metastases From Soild TumorsNCT06221072Shanghai JMT-Bio Inc.1,360
进行中（未招募）
3 期
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)Chronic Kidney Disease With High ProteinuriaNCT06087835AstraZeneca1,835
已完成
3 期
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent PatientsGastroesophageal Reflux Disease (GERD)NCT00241501AstraZeneca140